Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts)

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2011
This article has no abstract
Epistemonikos ID: ddfb3267a93f6065c742fb3b38fae442e8772061
First added on: Feb 04, 2025